News

Latest news

Hide mandatory notifications of trade

Fourth Quarter and Full-Year Results 2011

Oslo, 17.02.12 - Bionor Pharma ASA (OSE: BIONOR) today announced financial results for fourth quarter and full year 2011 and provided highlights of the key developments during the fourth quarter, current status and outlook.


This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Link to Q4 report.
 
Highlights Fourth Quarter 2011
  • Clinical study of nasal administration for Vacc-4x started at Oslo University Hospital in November.
  • Bionor Pharma's universal influenza vaccine Vacc-Flu was presented at Influenza Congress in Washington DC.
  • Vacc-C5 completed toxicological testing and was found to be safe and well tolerated
  • EBITDA Q4 2011 MNOK -14.7 and EBITDA for full year 2011 MNOK 57.4
  • Cash holdings MNOK 144.2 by end of Q4 2011.

 

Highlights after Fourth Quarter 2011

With final review of Phase IIb Viral Load data completed, the Company confirms statistically significant reduction of HIV Viral Load on Vacc-4x compared to placebo

  • Clinical study of nasal administration for Vacc-4x started at Oslo University Hospital has been fully enrolled.
  • Data to support the platform patent for cell-mediated immunity was submitted 3rd December 2011

 

Key Figures
Q4 2011 Q4 2010 (In NOK 1000) FY 2011 FY 2010
169 3 956 Revenue 109 499 12 591
-14 824 -13 012 Other operating expenses (net) -52 106 -47 838
-14 655 -9 056 EBITDA 57 393 -35 247
-2 834 -2 594 Depreciation -11 300 -9 224
  84 658 Write-down of intangible assets    
-17 489 73 008 EBIT 46 093 -44 471


Outlook

The conclusive data provide a basis for further HIV trials, offering Bionor three main pathways to market.

  • Bionor Pharma is planning an extensive clinical research program including:
    - Vacc-4x and Revlimid® in combination
    - Vacc-4x revaccination
    - Vacc-4x study involving nasal administration
    - Vacc-C5 phase I/II trial
  • Further development of vaccine candidates for HCV, influenza and potentially virus associated cancer.
  • The successful outcome of the phase IIb clinical trial, together with the Company`s further preclinical and clinical program, makes a partnering process a priority for Bionor Pharma


For further information:

Steen Krøyer, CEO                 +47 23 01 09 60

Gunnar Flåten, SVP Finance & Administration          +47 35 90 85 03 / +47 91 31 64 79